May 1, 2020

To: Center Medical Directors, Data Managers, and IRB PIs

From: Bronwen E Shaw, MD PhD
CIBMTR Associate Chief Scientific Director

Subject: COVID-19 Impact to CIBMTR Network Centers - UPDATE

On March 20, 2020, a memo from the CIBMTR was sent to Transplant Centers regarding steps CIBMTR was taking to lessen the burden on our centers. Our response to COVID-19 continues to evolve due to the fluid nature of the situation. The following information, processes, and guidelines will be continuously evaluated and updated as needed.

For the most up-to-date information, please visit our webpage dedicated to COVID-19 (https://www.cibmtr.org/Covid19/Pages/default.aspx).

The following have been updated:

CPI & CTA
CIBMTR is suspending CPI requirements until further notice for all product types (Allogeneic Related, Allogeneic Unrelated, Autologous, and Cellular Therapy (CT) infusions).
- Please note, during this time, your center must still have current IRB documents (renewal letters and consents) on file with NMDP
- CTA will be extended with a final due date of December 31, 2020.
- It is currently impossible to predict the impact of this situation on future CPI requirements; we will continue to communicate with you as the situation develops.

Consent to CIBMTR Research Repository
CIBMTR recommends sites continue to consent patients and submit samples, if safe for the patients and clinical staff. CIBMTR is suspending CPI requirements until further notice and will consider all missed samples as excused with no excuse code forms required.

Clinical Data Validation (Audit)
Due to the current travel restrictions, on-site CIBMTR Data Audits will continued to be evaluated at each scheduled site. The CIBMTR will reach out to each site eight weeks prior to the scheduled audit date via email. If the on-site audit cannot be conducted, we will assess the possibility of conducting the audit remotely. If this is not an option, sites will be rescheduled to a later date. The CIBMTR will continue to monitor the travel restrictions, as well as transplant center restrictions in order to reassess the plan for on-site audits resuming as soon as possible.
As a reminder, CIBMTR will continue to collect data and reimburse centers during this time. FormsNet3 is fully operational, including CIBMTR Center Support (http://nmdp.service-now.com/csm) to answer any of your center’s questions.

We ask that if your center is still submitting data, please prioritize:

1. Respiratory Virus Post-Infusion Data Form (2149)
2. Consecutive Transplant Audit (CTA)
3. Recipients on studies, especially BMT CTN

We will continue to communicate as the situation changes. If you have any questions or need clarification, please contact Eileen Tuschl, Data Operations-Sr. Manager of Customer Service and Education at etuschl@mcw.edu.